IRLAB Therapeutics (IRLAB) Q4 2024 earnings summary

Executive summary

• Advanced a robust pipeline with five first-in-class drug candidates for Parkinson's, achieving key milestones such as completion of patient treatment in the Phase IIb study for pirepemat, positive Phase I results for IRL757, and preparations for mesdopetam Phase III.

• Secured significant external funding and partnerships, including with The Michael J. Fox Foundation and MSRD/Otsuka, supporting clinical progress and fully funding IRL757 through proof-of-concept.

• Received pediatric study waivers from EMA and FDA for mesdopetam, reducing development time and costs.

• Positive regulatory and payer feedback for mesdopetam in the US and Europe, with strong commercial potential and new patents extending exclusivity into the 2040s.

• CEO transition in August 2024, with Kristina Torfgård emphasizing innovation and growth.

Financial highlights

• Year-end cash position was SEK 66.9M, with SEK 17M as prepayments from partners and net sales for 2024 reaching SEK 94.6M, up from SEK 5.7M in 2023.

• Operating loss narrowed to SEK -75.1M from SEK -180.8M year-over-year, and EPS improved to SEK -1.6 from SEK -3.43.

• Net loss for the year was SEK -83.1M, compared to SEK -177.8M in 2023.

• R&D costs totaled SEK 163.7M, representing 87% of operating expenses.

• Headcount stable at 31 employees.

Outlook and guidance

• Topline data from the Phase IIb study of pirepemat expected in Q1 2025, with potential expansion into dementia indications.

• Preparations for mesdopetam Phase III ongoing, with business development activities and strong commercial potential confirmed by payer research.

• IRL757 is progressing as planned, with plans to start patient studies later in the year and development fully funded through proof-of-concept.

• IRL942 and IRL1117 are advancing toward Phase I, with IND-enabling studies targeted for this year and Phase I readiness projected for 2025.

• Active pursuit of new licensing, partnership, and financing agreements to secure future funding.